191 related articles for article (PubMed ID: 11241842)
1. Molecular analysis of acid ceramidase deficiency in patients with Farber disease.
Bär J; Linke T; Ferlinz K; Neumann U; Schuchman EH; Sandhoff K
Hum Mutat; 2001 Mar; 17(3):199-209. PubMed ID: 11241842
[TBL] [Abstract][Full Text] [Related]
2. The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression.
Li CM; Park JH; He X; Levy B; Chen F; Arai K; Adler DA; Disteche CM; Koch J; Sandhoff K; Schuchman EH
Genomics; 1999 Dec; 62(2):223-31. PubMed ID: 10610716
[TBL] [Abstract][Full Text] [Related]
3. Human acid ceramidase gene: novel mutations in Farber disease.
Zhang Z; Mandal AK; Mital A; Popescu N; Zimonjic D; Moser A; Moser H; Mukherjee AB
Mol Genet Metab; 2000 Aug; 70(4):301-9. PubMed ID: 10993717
[TBL] [Abstract][Full Text] [Related]
4. Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes.
Li CM; Park JH; Simonaro CM; He X; Gordon RE; Friedman AH; Ehleiter D; Paris F; Manova K; Hepbildikler S; Fuks Z; Sandhoff K; Kolesnick R; Schuchman EH
Genomics; 2002 Feb; 79(2):218-24. PubMed ID: 11829492
[TBL] [Abstract][Full Text] [Related]
5. A fluorescence-based high-performance liquid chromatographic assay to determine acid ceramidase activity.
He X; Li CM; Park JH; Dagan A; Gatt S; Schuchman EH
Anal Biochem; 1999 Oct; 274(2):264-9. PubMed ID: 10527524
[TBL] [Abstract][Full Text] [Related]
6. Farber lipogranulomatosis: clinical and molecular genetic analysis reveals a novel mutation in an Indian family.
Devi ARR; Gopikrishna M; Ratheesh R; Savithri G; Swarnalata G; Bashyam M
J Hum Genet; 2006; 51(9):811-814. PubMed ID: 16951918
[TBL] [Abstract][Full Text] [Related]
7. [Farber disease [Farber lipogranulomatosis], acid ceramidase deficiency].
Koga M
Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):389-93. PubMed ID: 9645089
[No Abstract] [Full Text] [Related]
8. Mutation analysis of the acid ceramidase gene in Japanese patients with Farber disease.
Muramatsu T; Sakai N; Yanagihara I; Yamada M; Nishigaki T; Kokubu C; Tsukamoto H; Ito M; Inui K
J Inherit Metab Dis; 2002 Nov; 25(7):585-92. PubMed ID: 12638942
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.
Alves MQ; Le Trionnaire E; Ribeiro I; Carpentier S; Harzer K; Levade T; Ribeiro MG
Mol Genet Metab; 2013 Jul; 109(3):276-81. PubMed ID: 23707712
[TBL] [Abstract][Full Text] [Related]
10. Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency.
Iacobazzi V; Invernizzi F; Baratta S; Pons R; Chung W; Garavaglia B; Dionisi-Vici C; Ribes A; Parini R; Huertas MD; Roldan S; Lauria G; Palmieri F; Taroni F
Hum Mutat; 2004 Oct; 24(4):312-20. PubMed ID: 15365988
[TBL] [Abstract][Full Text] [Related]
11. Sulfatide and sphingomyelin loading of living cells as tools for the study of ceramide turnover by lysosomal ceramidase--implications for the diagnosis of Farber disease.
Levade T; Tempesta MC; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
Biochem Mol Med; 1995 Apr; 54(2):117-25. PubMed ID: 8581356
[TBL] [Abstract][Full Text] [Related]
12. Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of the first molecular lesion causing Farber disease.
Koch J; Gärtner S; Li CM; Quintern LE; Bernardo K; Levran O; Schnabel D; Desnick RJ; Schuchman EH; Sandhoff K
J Biol Chem; 1996 Dec; 271(51):33110-5. PubMed ID: 8955159
[TBL] [Abstract][Full Text] [Related]
13. Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies.
Chatelut M; Harzer K; Christomanou H; Feunteun J; Pieraggi MT; Paton BC; Kishimoto Y; O'Brien JS; Basile JP; Thiers JC; Salvayre R; Levade T
Clin Chim Acta; 1997 Jun; 262(1-2):61-76. PubMed ID: 9204210
[TBL] [Abstract][Full Text] [Related]
14. [Farber's lipogranulomatosis].
Koga M
Nihon Rinsho; 1995 Dec; 53(12):3009-13. PubMed ID: 8577050
[TBL] [Abstract][Full Text] [Related]
15. Overexpression and mass spectrometry analysis of mature human acid ceramidase.
Schulze H; Schepers U; Sandhoff K
Biol Chem; 2007 Dec; 388(12):1333-43. PubMed ID: 18020949
[TBL] [Abstract][Full Text] [Related]
16. Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells.
Levade T; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
J Neurol Sci; 1995 Dec; 134(1-2):108-14. PubMed ID: 8747852
[TBL] [Abstract][Full Text] [Related]
17. Glycogenosis type II: identification and expression of three novel mutations in the acid alpha-glucosidase gene causing the infantile form of the disease.
Montalvo AL; Cariati R; Deganuto M; Guerci V; Garcia R; Ciana G; Bembi B; Pittis MG
Mol Genet Metab; 2004 Mar; 81(3):203-8. PubMed ID: 14972326
[TBL] [Abstract][Full Text] [Related]
18. Molecular analyses of novel ASAH1 mutations causing Farber lipogranulomatosis: analyses of exonic splicing enhancer inactivating mutation.
Bashyam MD; Chaudhary AK; Kiran M; Reddy V; Nagarajaram HA; Dalal A; Bashyam L; Suri D; Gupta A; Gupta N; Kabra M; Puri RD; RamaDevi R; Kapoor S; Danda S
Clin Genet; 2014 Dec; 86(6):530-8. PubMed ID: 24355074
[TBL] [Abstract][Full Text] [Related]
19. Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells.
Medin JA; Takenaka T; Carpentier S; Garcia V; Basile JP; Segui B; Andrieu-Abadie N; Auge N; Salvayre R; Levade T
Hum Gene Ther; 1999 May; 10(8):1321-9. PubMed ID: 10365663
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of two novel mutations causing factor XI deficiency: A splicing defect and a missense mutation responsible for a CRM+ defect.
Guella I; Soldà G; Spena S; Asselta R; Ghiotto R; Tenchini ML; Castaman G; Duga S
Thromb Haemost; 2008 Mar; 99(3):523-30. PubMed ID: 18327400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
